Business
Resverlogix Announces New Data on Autoimmune Program featured at World Congress of Inflammation
Jun. 27, 2011 (Canada NewsWire Group) -- TSX Exchange Symbol: RVX CALGARY, June 27, 201...
About this update from Resverlogix Corp.
[{"type":"text","content":"\n\n\n Jun. 27, 2011 (Canada NewsWire Group) -- \n\n#ReleaseContent TABLE\n{\n BORDER-COLLAPSE: collapse\n}\nTR.cnwUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 1px solid\n}\nTR.cnwDoubleUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 3px double\n}\nTR.cnwBoldUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 3px solid\n}\nTD.cnwUnderlinedCell\n{\n BORDER-BOTTOM: #000000 1px solid\n}\nTD.cnwDoubleUnderlinedCell\n{\n BORDER-BOTTOM: #000000 3px double\n}\nTD.cnwBoldUnderlinedCell\n{\n BORDER-BOTTOM: #000000 3px solid\n}\n#ReleaseContent TABLE.cnwBorderedTable TD\n{\n BORDER-RIGHT: black 1px solid;\n PADDING-RIGHT: 2px;\n BORDER-TOP: black 1px solid;\n PADDING-LEFT: 2px;\n PADDING-BOTTOM: 2px;\n BORDER-LEFT: black 1px solid;\n PADDING-TOP: 2px;\n BORDER-BOTTOM: black 1px solid;\n BORDER-COLLAPSE: collapse\n}\n#ReleaseContent TABLE TD\n{\n PADDING-RIGHT: 2px;\n PADDING-LEFT: 2px;\n PADDING-BOTTOM: 2px;\n PADDING-TOP: 2px\n}\n\n\nTSX Exchange Symbol: RVX\n\n\nCALGARY, June 27, 2011 /CNW/ - Resverlogix Corp. ("Resverlogix")\n (TSX:RVX) is pleased to announce today that key scientific data has\n been presented in a poster presentation highlighting the novel features\n of RVX-297, at the 10th World Congress on Inflammation, in Paris,\n France (poster number P-296, June 27 at 1 pm). The presentation is\n entitled "An Orally Bioavailable Small Molecule RVX-297 Significantly Decreases\n Clinical Signs In A Mouse Model Of Multiple Sclerosis."\n\n\n"RVX-297 is a representative molecule from our autoimmune program, which\n was established to expand upon important discoveries made during our\n investigative research on pharmacological approaches for controlling\n the inflammatory components of atherosclerosis," stated Don McCaffrey,\n President & CEO of Resverlogix.\n\n\nMr. McCaffrey continued, "Autoimmune diseases such as multiple\n sclerosis, rheumatoid arthritis, psoriasis and Crohn's disease\n currently represent a significant unmet medical need globally. The\n novel, orally bioavailable small molecule drugs under development by\n Resverlogix possess unique immunopharmacological properties and have\n the potential to compete effectively against expensive protein-based\n therapeutics which currently dominate the autoimmune market."\n\n\nThe poster presentation includes data demonstrating that...